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Background: Acute Respiratory Distress Syndrome (ARDS) is a condition that contributes to morbidity and
mortality of critically ill patients. We investigated whether factors secreted by adipose stromal cells (ASC) into
conditioned media (ASC-CM) will effectively decrease lung injury in the model of lipopolysaccharide (LPS)-induced
ARDS.
Methods: To assess the effect of ASC-CM on ARDS indices, intravenous delivery of ASC and ASC-CM to C57Bl/6 mice
was carried out 4 h after LPS oropharyngeal aspiration; Evans Blue Dye (EBD) was injected intravenously 1 h prior to
animal sacrifice (48 h post-LPS). Lungs were either fixed for histopathology, or used to extract bronchoalveolar lavage
fluid (BALF) or EBD. To assess the effect of ASC-CM on endothelial barrier function and apoptosis, human pulmonary
artery endothelial cells were treated with ASC-CM for 48-72 h.
Results: ASC-CM markedly reduced LPS-induced histopathologic changes of lung, protein extravasation into BALF,
and suppressed the secretion of proinflammatory cytokines TNFα and IL6. White Blood Cells (WBC) from BALF of
LPS-challenged mice receiving ASC-CM had decreased reactive oxygen species (ROS) generation compared to WBC from
LPS-challenged mice receiving control media injection. Treatment of pulmonary endothelial monolayers with ASC-CM
significantly suppressed H2O2-induced leakage of FITC dextran and changes in transendothelial resistance, as well as gap
formation in endothelial monolayer. ASC-CM exposure reduced the percentage of endothelial cells expressing ICAM-1, and
suppressed TNFα-induced expression of E-selectin and cleavage of caspase-3. ASC-CM reduced the endothelial level of
pro-apoptotic protein Bim, but did not affect the level of Bcl-2, Bad, or Bad phosphorylation.
Conclusions: Factors secreted by ASC efficiently reduce ARDS indices, endothelial barrier hyperpermeability, and activation
of pro-inflammatory and pro-apoptotic pathways in endothelium.
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ARDS is a serious condition resulting in respiratory failure
and increased morbidity and mortality of critically ill pa-
tients [1,2]. ARDS can be triggered by a variety of pulmon-
ary causes, such as viral infection, pneumonia, aspiration of
gastric content, lung contusion, as well as non-pulmonary
causes including sepsis, burn injury, multiple trauma, and* Correspondence: nbogatch@iu.edu
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unless otherwise stated.acute pancreatitis [3]. The pathogenesis of ARDS includes
inflammation of the lung parenchyma, infiltration of neutro-
phils into the airspaces, oxidative stress, disruption of the
endothelial and epithelial barriers, damage to the epithelial
lining and subsequent lung fibrosis [4]. Despite the fact that
the mechanisms contributing to the pulmonary failure are
well delineated, more than 20 years of clinical trials show
that approaches aiming at the separate components of
pathogenesis fail to affect mortality [5]. Currently, ARDS
treatment remains primarily supportive. This situation high-
lights a need for a novel complex therapy, which would both
limit the pathogenic mechanisms of ARDS and facilitateis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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stromal cells (MSC) may provide such multi-directional
therapeutic action, as mesenchymal stromal cells exert
pleiotropic effects, including anti-inflammatory and regen-
erative activities [8].
Initial studies exploring the effects of MSC on lung
injury in rodents and explanted human lungs utilized bone
marrow-derived mesenchymal stromal cells (MSC). These
studies have shown that MSC suppressed lung injury in
LPS- [9-11], Escherichia coli- [12], cecal ligation/punc-
ture- [13,14], and bleomycin-induced [15] lung injury
models. More recently, there has been increased interest
in investigating MSC derived from adipose tissue (ASC) as
a therapy for ARDS. The potential advantage of using
ASC is their rapid isolation in therapeutic amounts via
enzymatic digestion of the autologous adipose tissue har-
vested by liposuction, unlike MSC, which typically require
weeks of propagation for a similar cell yield [16]. Similar
to MSC, ASC are effective in inhibiting lung damage in
ARDS in LPS- [17-20], cecal ligation/puncture- [21],
ventilation- [22] and ischemia-reperfusion-induced [23]
lung injury models.
While some studies have reported relatively high level of
stem cell engraftment (ranging from 9-16% of cells admin-
istered intravenously) [24] and trans-differentiation into
pulmonary cells [25], most studies emphasize stem cell-
mediated anti-inflammatory effects along with stimulation
of phagocytosis and bacterial clearance [9-13,15]. These
effects have been attributed to secreted soluble factors
from stem cells, and more recently to mitochondrial trans-
fer from stem to host cells [26]. How effective are secreted
soluble factors compared to the physical presence of ASC
in ARDS therapy is an important question to answer, as
the ability to use of-the-shelf conditioned media for thera-
peutic purposes will have obvious advantages compared to
the use of banked or autologous cells.
In the current study, we compared the effects of ASC
and ASC-CM on lung injury in a murine model of LPS-
induced ARDS and analyzed the effects of ASC-CM on
endothelium in vitro. The results of our study provide
insight into the mechanisms of ASC beneficial action on
inflamed lung, and have implications for the development
of new cell-free therapy.
Materials and methods
Materials
E. coli LPS 0127:B8 with the lot activity of 3,000,000 U/mg,
and 40 kDa fluorescein isothiocyanate (FITC)-dextran were
purchased from Sigma (St. Louis, MO). The antibody rec-
ognizing VE-cadherin was from Cayman Chemical (Ann
Harbor, MI); antibody to cleaved caspase-3 was from Cell
Signaling (Beverly, MA); antibodies to Bcl-2 and Bad were
from Santa Cruz Biotechnology (Dallas, TX); antibodies to
phospho-Bad and Bim were from Cell Signaling (Beverly,MA), antibody to β-actin was from Sigma (St. Louis, MO).
Carboxy-dichlorofluorescein diacetate (carboxy-DCFH-DA),
and all reagents used for immunofluorescent staining were
obtained from Invitrogen (Carlsbad, CA). All reagents for
Flow Cytometry were from BD Biosciences (San Jose, CA).
Animals
Male C57BL/6 mice were purchased from Harlan
(Indianapolis, IN). All animal procedures were approved
by Indiana University Institutional Animal Care and Use
Committee and conformed to the requirements of Animal
Welfare Act.
Cell culture
All procedures for collecting human adipose tissue were
approved by the Indiana University School of Medicine
Institutional Review Board. Human ASC (hASC) were iso-
lated from human subcutaneous adipose tissue samples ob-
tained from liposuction procedures as previously described
[27] and used at passage 3. Human pulmonary artery
endothelial cells (HPAEC) were purchased from Lonza
(Walkerville, MD) and used at passages 5–8. Murine ASC
(mASC) were isolated from subcutaneous fat from the hip
area using a similar procedure. Briefly, fat was excised from
the anesthetized animal, minced and digested with 2 mg/ml
collagenase type 1 (Worthington) at 37°C. Digests were cen-
trifuged at 300 g to separate floating adipocytes. The pellet
containing stromal vascular fraction was re-suspended in
basal medium (EBM2 (Lonza)) supplemented with 5% FBS,
filtered through 100 μ nylon filter, and centrifuged again at
300 g. Cells were re-suspended in complete growth medium
(EGM2-MV (Lonza)), allowed to adhere to plastic, and
propagated in EGM2-MV until 3rd passage at 37°C in a
humidified atmosphere of 5%CO2-95% air. Before injection,
cells were trypsinized and re-suspended in EBM2 at a
concentration of 3 × 106cell/mL.
Flow cytometry
mASC passage 3 were harvested, counted with hemo-
cytometer, and incubated for 20 min on ice with
fluorophore-labeled anti-Sca-1 (positive selection marker),
anti-CD31 and anti-CD45 (negative selection markers) IgG.
Human ASC were tested for expression of CD13, CD73,
CD90, CD105 (positive selection markers), CD31, and
CD45 markers. Corresponding IgG were used as isotype
controls. Flow cytometry was performed using a Calibur
flow cytometer and Cell QuestPro software (BD).
Generation of conditioned media
The composition of the media used for ASC-CM prepar-
ation was chosen depending on the nature of the following
assay. Conditioned media for the assessment of the hASC-
CM effects on endothelial permeability had to support
HPAEC endothelial barrier over the pre-incubation period,
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EGM2-MV. 50-60% confluent ASC were incubated with
fresh EGM2MV 0.2 mL/cm2; media was collected 24 h
later, and kept frozen until future analysis. Conditioned
media for animal injections had to be FBS-free, and there-
fore was generated from mASC using basal EBM2 with
0.5% C57BL/6 mouse serum (Innovative Research, Novi,
MI). When mASC-CM was generated, cells were allowed
to reach same density as in the experiment when mASC
were expanded for injection. Generated mouse ASC-CM
(11 ml per 106 cells) was concentrated 10 times with
3 kDa cut-off filter (Amicon, Billerica, MS) to render
1.1 ml of product per 106 cells. mASC-CM was kept fro-
zen until injection into animals. With this concentration,
injection of 0.2 ml of mASC-CM is equivalent to the injec-
tion of factors generated by ~ 180 000 ASC. Correspond-
ing base media (EBM2 with 0.5% C57BL/6 mouse serum)Figure 1 Surface marker expression of mASC (A) and hASC (B). IC-isot
of mASCs expressed the surface antigen of mesenchymal stem cells Sca-1,
endothelial marker (CD31). The majority of hASC expressed stromal markerwas subjected to identical manipulations and used for
control injections in ASC-CM experiment.
Assessment of ARDS indices
LPS (2 mg/kg of body weight) or an equal volume of saline
was delivered to isoflurane-anesthetized 20-25 g C57BL/6
mice by oropharyngeal aspiration (OA), as described in
[20]. Body temperature assessment was performed in alert
animals using a rectal probe (YSI Life Sciences, Yellow
Springs, OH).
In ASC experiments, either 360,000 murine ASC re-
suspended in basal media EBM2 (passage 3) or equivalent
volume of EBM2 (0.1 mL) were injected into tail vein 4 h
after LPS administration. In ASC-CM experiments 0.2 mL
of concentrated ASC-CM or corresponding control media
were injected. Twenty-four or 48 h later, animals were
sacrificed for analysis. For the assessment of vascular leakype controls, AS- antigen-specific antibodies. As expected, the majority
and was negative for the hematopoietic stem cell marker (CD45) and
s CD13, CD73, CD90, and CD105, and was negative for CD31, CD45.
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EBD/ 4% BSA solution in saline) was administered in
the tail vein (30 mg/kg) 1 h prior to experiment termin-
ation. The chest cavity was opened under anesthesia
and blood was sampled by cardiac puncture to deter-
mine level of circulating EBD. After nicking left atrium
and severing abdominal aorta and vena cava, lungs were
washed from blood by injecting saline via the right ven-
tricle. Bronchoalveolar lavage fluid (BALF) was obtained
by flushing lungs via trachea with 3 mL ice-cold PBS.
Lungs were excised and homogenized in formamide to
extract EBD (18 h, 60°C); optical density was determined at
620 and 750 nm. Extravasated EBD concentration was
calculated using a standard curve and normalized to plasma
EBD level. BALF was centrifuged at 600 g to sediment cells;
supernatant was snap-frozen for future ELISA and protein
content analyses. Pellet was subjected to red cell lysis;B


























Figure 2 Administration of ASC/ASC-CM is scheduled at the onset of
measured in mice receiving saline (black) or LPS (grey) via oropharyngeal a
at 8 a.m. Black lines indicate periods of dark. C. Total WBC (T, dark grey) an
(N = 3 per group). BALF was collected 4 h post-saline/LPS administration. T
between analyzed groups.remaining cells were separated by cytospin and stained with
Diff Quick staining kit (ThermoFisher Scientific, Waltham,
MA). Cells were identified under Nikon microscope 40x
objective; total of 300 cells were counted on each slide.
For immunohistochemistry, lungs were perfused with 4%
formaldehyde/agarose solution, embedded in paraffin, sec-
tioned and analyzed with Nikon microscope (10x magnifi-
cation objective).
ELISA analyses
Mouse Quantikine ELISA kits were from R&D Systems
(Minneapolis, MN). Undiluted BALF stored at −80° was
used to determine concentrations of TNFα, IL-6, IL-10,
MIP-2, and VEGF; all analyses were run in duplicate. Cyto-
kine content in BALF was determined by multiplying cyto-
kine concentration (pg/mL) by the exact volume of BALF

























ARDS. A. Timeline of the in vivo study design. B. Body temperature
spiration (N = 3-4 per group). First time point of the day was recorded
d neutrophil (N, white) count in BALF of mice receiving saline or LPS
-test with Welch’s correction was used to assess the differences
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The method for the measurement of oxidative activation of
neutrophils was based on the ROS-dependent oxidation of
carboxy-DCFH-DA to carboxy-DCF [28]. Cells from BALF
of LPS- and LPS/ASC-CM treated mice were placed in
wells of 96-well plate (60,000 cells per well), pre-loaded
with 12.5 μg/ml carboxy-DCFH-DA, and then stimulated
with 1 μg/ml LPS for 20 h. Wells with no cells containing
the same concentration of dye were used as controls. Fluor-
escence was read in the FITC channel of fluorometer/plate
reader. All assays were run in triplicate.
Measurement of transendothelial permeability
Permeability of HPAEC monolayers for FITC-dextran was
measured using 0.4 μ polyester trans-well inserts (Costar)
as described in [29]. Briefly, HPAEC were plated on
collagen-coated inserts, whereas ASC or NHDF were platedFigure 3 mASC and mASC-CM markedly reduce LPS-induced lung inju
magnification. B. High power fields at the time points indicated. Note the t
the airspaces in response to LPS (arrows).on the bottom of wells. HPAEC were allowed to reach
confluency. Alternatively, HPAEC were pretreated with un-
concentrated ASC or NHDF conditioned media mixed with
EGM2MV (1:1) for 72 h. Media were changed to EBM-2
(Lonza) 1 h prior to FITC-dextran loading. FITC-dextran
was added to the top chamber to a final concentration
1.75 mg/mL; immediately after, monolayers were stimulated
with 0.25 mM H2O2. After 2 h, media was sampled from
the bottom chamber and analyzed for FITC-dextran fluor-
escence. All analyses were run in quadruplicate.
Transendothelial electrical resistance (TER) was mea-
sured using the highly sensitive biophysical assay with
an electrical cell-substrate impedance sensor (ECIS)
(Applied Biophysics, Troy, NY) as described previously
[29]. HPAEC were plated on gold microelectrodes in
EGM2MV; then exposed to the un-concentrated condi-
tioned media/EGM2MV mixture (1:1) for 72 h. At thery. A. Histopathology of lung 48 h post-saline/LPS shown at 10X
hickening of alveolar wall and the appearance of cellular infiltrate in
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reached 1000–1200 Ohms, evident of monolayer con-
fluence. Media were changed to basal media 1 h prior to
the beginning of the TER recording. 30 min after the
start of recording, monolayers were stimulated with
0.25 mM H2O2.
HPAEC imaging
For immunofluorescence experiments, HPAEC monolayers
were plated on gelatin-coated coverslips and grown to con-
fluence. Cells were exposed to the un-concentrated condi-
tioned media mixed with EGM2-MV (1:1) for 72 h; media
were changed to EBM2 1 h prior to the beginning of the
experiment. After H2O2 stimulation, cells were fixed, perme-
abilized and stained with VE-cadherin-specific antibodies
and Alexa594-conjugated phalloidin. Coverslips were viewed
and photographed using Nikon fluorescent microscope
(40x objective).Figure 4 mASC and mASC-CM effect on epithelial and endothelial perm
reduced by mASC-CM (B), but not mASC (A). Conversely, EBD content in lung
Anova with Tukey post-hoc was used to assess the significance of differencesAssessment of VCAM, ICAM-1, and E-selectin expression
HPAEC grown in 6 well plates were exposed to the un-
concentrated conditioned media mixed with EGM2-MV
(1:1) for 72 h; media were changed to EBM2 1 h prior to
the beginning of the experiment. 4 h after TNFα/vehicle
control stimulation, cells were harvested and incubated
with fluorescently labeled IgG against CD54/ICAM-1
(eBioscience, San Diego, CA), CD62E/E-selectin (Biolegend,
San Diego, CA), and CD106/VCAM (BD) on ice for 30 mi-
nutes. Labeled cells were analyzed with Guava 8HT flow
cytometer ((EMD Millipore, Billerica, MA).
Western immunoblotting
HPAEC grown in 12-well plates were exposed to the un-
concentrated conditioned media mixed with EGM2-MV
(1:1) for 48-72 h; media were changed to EBM2 1 h
prior to the beginning of the experiment. After 4 h
stimulation with TNFα, cells were rinsed with ice-coldeability. Protein in BALF collected 48 h post-injection was significantly
was significantly reduced by mASC (C), but not mASC-CM (D). One-way
between the groups; number of animals is indicated.
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extracts were separated on 4-20% gels and transferred to
nitrocellulose membrane. After staining with specific
antibodies, membranes were developed and scanned
using BioRad imaging system.
Statistical analysis
Quantitative data are presented as mean ± SEM, unless
otherwise indicated. Statistical analysis was performed by
t-test, t-test with Welch’s correction (unequal variance),
One-way ANOVA with Tukey post-hoc or Repeated Mea-
sures One-way ANOVA using GraphPad Prizm6 or Origin
8.0 software. Shapiro-Wilk test was used to confirm that
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Figure 5 mASC and mASC-CM effect on neutrophil numbers and activity.
reduced by mASC (A), but not mASC-CM (B). The ratio between macrophages (M
significantly affected by either experimental treatment. N = 5-6 animals per group
vehicle (LPC cn) or 1 μg/ml LPS stimulation (LPS st). In parallel, WBC from BALF o
(LPS/CM cn) or LPS stimulation (LPS/CM st). LPS-induced ROS generation by WBC
WBC from BALF of LPS/media mice. T-test was used to analyze the significance oA probability value of < 0.05 was considered statistically
significant.
Results
Flow cytometric analyses of ASC surface markers
Both murine and human ASC used in our study were
produced by propagation of the cell fraction adherent to
plastic under standard culture conditions. mASC and
hASC demonstrated typical size, spindle shape, and
morphology in culture consistent with adipose stem
cells. mASC as well as hASC were evaluated with re-
spect to their surface marker phenotype at passage 3.
mASC were positive for Sca-1, one of the markers rou-
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Total WBC (T, grey) and PMN (N, white) counts in BALF were significantly
), lymphocytes (L) and neutrophils (N) in BALF of LPS-treated mice was not
. (C)WBC from BALF of LPS-challenged mice (N = 6) were subjected to
f LPS/ASC-CM-treated mice (N= 6) were subjected to vehicle control
from BALF of LPS/ASC-CM mice was significantly lower comparing to
f differences between groups.
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marker CD31 and the marker of cells of hematopoietic
origin CD45 (Figure 1A). Similarly, analysis of hASC at
passage 3 demonstrated positive staining for the stromal
markers CD13, CD73, CD90 and CD105 and negative
staining for CD31 and CD45 (Figure 1B).Study design
LPS or saline were delivered into lungs through oropharyn-
geal aspiration (Figure 2A). Intravenous ASC, ASC-CM or
control media injections were performed 4 h after LPS deliv-
ery. This protocol was designed to schedule the ASC admin-
istration concurrently with the onset of ARDS, identified by
peak of hypothermia at 4 h following LPS administration
(Figure 2B) and by the first presence of neutrophil infiltra-
tion in BALF (Figure 2C).Effect of ASC or ASC-CM on lung histopathology
following LPS administration
Hematoxylin and eosin staining of the lung sections
revealed no apparent signs of inflammatory response in
saline-treated lungs of mice which received ASC or con-
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Figure 6 mASC and mASC-CM effect on pro-inflammatory cytokines in BA
MIP-2 (E-F). One-way Anova with Tukey post-hoc was used to assess the significainflammation, which was evident at 24 h and severe at
48 h. In mice receiving control media injection, LPS
caused marked infiltration of neutrophils and red blood
cells into the lung interstitium and airspaces, as well as
swelling of the alveolar walls. In contrast, systemic deliv-
ery of ASC or ASC-CM reduced septum thickening and
suppressed accumulation of cells and debris in the
alveolar sacs (Figure 3).
ASC and ASC-CM effects on lung permeability and
neutrophil infiltration
Assessment of total protein content in BALF showed a
significant increase of protein level in response to LPS ad-
ministration (Figure 4 A,B). While ASC treatment had no
effect on LPS-induced protein increase in BALF, ASC-CM
treatment markedly suppressed the LPS-induced protein
increase 48 h post-injection. On the contrary, ASC were
able to suppress LPS-induced increase in EBD extravasa-
tion (Figure 4C), whereas ASC-CM effect was not signifi-
cant (Figure 4D).
Assessment of total WBC count in BALF showed that
the number of cells in airspaces increased dramatically in
response to LPS stimulation (Figure 5A,B). Whereas resi-
dent lung macrophages comprised the majority of cells inM LPS/med LPS/CM
*
            6            6
C LPS/med LPS/ASC
*
            6            5
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F
LF.mASC and mASC-CM reduced the level of TNFα and IL6 (A-D), but not
nce of differences between the groups; number of animals is indicated.
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type in BALF from LPS-challenged lungs. Although ASC
or ASC-CM treatment did not shift the overall neutro-
phil/macrophage balance (Figure 5A,B), a significant sup-
pression of total WBC count was evident in LPS mice
receiving ASC injection (Figure 5A). A similar trend was
observed in mice receiving ASC-CM, but did not reach
significance at 48 h post-injection (Figure 5B). To further
characterize possible mechanisms of ASC-CM-mediated
lung injury limitation, we compared the ability of BALF
WBC, obtained from LPS- or LPS/ASC-CM-receiving
mice, to generate ROS. The method for the measurement
of neutrophils oxidative activity was based on ROS-
dependent oxidation of DCFH-DA (non-fluorescent) to
highly fluorescent DCF. Isolated BALF WBC were tested
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Figure 7 mASC and mASC-CM effect on the level of anti-inflammatory
BALF of LPS-challenged mice injected with mASC (A), but not mASC-CM (dat
response to mASC-CM injection (C), but not mASC injection (B). One-way An
differences between the groups; number of animals is indicated.stimulation in vitro. We observed that WBC from mice
receiving LPS can be further induced by LPS stimulation,
whereas WBC from mice receiving LPS/ASC-CM no longer
respond to LPS stimulation (Figure 5C), suggesting that
mice exposure to ASC-CM leads to lung recruitment of
neutrophils with a reduced potential for oxidative response.
ASC and ASC-CM effects on accumulation of pro- and
anti-inflammatory cytokines and pro-angiogenic factor in
BALF
To determine the effect of ASC and ASC-CM on inflam-
mation progression/resolution, we assessed the level of the
pro-inflammatory cytokines TNFα, IL6, and MIP-2, and
anti-inflammatory IL10 in BALF. LPS caused marked in-
crease in the level of TNFα, IL6 and MIP-2 (Figure 6A-F).
Forty-eight hours after cell or conditioned media injection,LPS LPS+ASC
C
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cytokine IL10 and pro-angiogenic factor VEGF. IL10 was detected in
a not shown). LPS-induced increase in VEGF level was reduced in
ova with Tukey post-hoc was used to assess the significance of
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pressed by both agents, whereas the increase in MIP-2
level was not affected significantly. The level of anti-
inflammatory IL10 remained below detection in control
mice as well as mice challenged with LPS. Significant
increase in BALF IL10 content was observed in response to
ASC (Figure 7A), but not ASC-CM (data not shown). Inter-
estingly, the LPS-induced level of VEGF in BALF was non-
significantly increased in ASC-treated mice, but markedly
suppressed in ASC-CM-treated mice (Figure 7B-C).
ASC and ASC-CM effects on endothelial permeability
in vitro
To further analyze mechanisms underlying ASC and
























Figure 8 hASC and hASC-CM preserve HPAEC transendothelial perme
electrodes of ECIS arrays (C) in the absence/presence of NHDF/hASC (A), o
the contact with cells/media; then stimulated with 250 μM H2O2. T-test wit
analyzed groups. NHDF and NHDF-CM were used for comparison as a non
parallel recordings for each pretreatment/stimulation: 1) unstimulated HPA
hASC-CM; 3) stimulated with H2O2 HPAEC which were not pretreated with
NHDF-CM; 5) stimulated with H2O2 HPAEC pretreated with hASC-CM. Repe
between response of NHDF-CM-pretreated cells and response of ASC-CM p
or hASC-CM reduced H2O2-induced hyperpermeability of HPAEC to FITC-deASC/ASC-CM effects on monolayer barrier function of
well-characterized human pulmonary endothelial cell line
HPAEC. Since recently it was suggested that syngeneic
ASC therapy has more potent effect than xenogeneic
therapy [20], we tested the effect of hASC/hASC-CM on
the permeability of human pulmonary endothelium. First,
HPAEC monolayers were grown on collagen-coated poly-
ester inserts in the presence of hASC or NHDF (as a non-
stem control) in the lower chamber. Prior to analysis,
inserts were transferred to fresh wells to avoid the possi-
bility of direct ROS scavenging by hASC/NHDF. The top
chamber was loaded with FITC-dextran, and monolayers
were stimulated with H2O2, the edemagenic product of
the neutrophil oxidative burst. We observed marked
HPAEC barrier dysfunction in response to H2O2, whichB
control H2O2 control H2O2 control H2O2
nopretreatment NHDF CM ASC CM
*




ability. HPAEC were grown on polyester inserts (A-B) or on gold
r NHDF/hASC conditioned media (B-C). HPAEC were removed from
h Welch’s correction was used to assess the differences between
-stem cell/conditioned media control. (C) Shown are the means of 3
EC pretreated with NHDF-CM; 2) unstimulated HPAEC pretreated with
CM; 4) stimulated with H2O2 HPAEC which were pretreated with
ated measures One-way ANOVA showed significant differences
retreated cells. Preincubation of endothelial monolayers with hASC
xtran (A-B) or to ions (C).
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presence of hASC (Figure 8A). We next pretreated HPA
EC monolayers with either hASC-CM or NHDF-CM.
Similar to HPAEC grown in the presence of hASC, HPAEC
grown in the presence of hASC-CM responded to H2O2
with less barrier dysfunction (Figure 8B); this stabilizing
effect was not seen with NHDF-CM. To further characterize
the hASC-CM-mediated stabilization of HPAEC barrier, we
assessed transendothelial electrical resistance (TER). HPAEC
grown on gold electrodes were pretreated with hASC-CM
or NHDF-CM; then stimulated with H2O2. Control mono-
layers responded to H2O2 with marked reduction of TER,
which was restored within 3 h. NHDF-CM-pretreated
monolayers displayed a similar response curve, whereas
hASC-CM-pretreated monolayers had a significantly attenu-
ated barrier dysfunction in response to H2O2 (Figure 8C).
Immunofluorescent microscopy of NHDF-CM-pretreated
HPAEC showed that H2O2 caused marked rearrangement
of the actin cytoskeleton along with distortion of junctional
organization and gap formation in endothelial monolayers
(Figure 9, arrowheads). hASC-CM-pretreated HPAEC dis-
played less severe changes in response to H2O2, with attenu-
ated gap formation.
ASC-CM effect on the expression of ICAM-1 and E-selectin
in endothelium
To ascertain whether hASC-CM anti-inflammatory
effect is dependent on the suppression of endothelial ex-
pression of leucocyte receptors, we assessed the level of
expression of VCAM, ICAM-1, and E-selectin in naïve
and TNFα-stimulated HPAEC. Low percentage of un-
stimulated cells appeared positive for VCAM (data not














Figure 9 hASC-CM preserves microscopic HPAEC monolayer integrity
H2O2-induced rearrangement of F-actin cytoskeleton and disintegration of
previously intact monolayer in response to H2O2.was detected in at least 70% cells (Figure 10). TNFα
caused dramatic increase in the percentage of VCAM-
(data not shown) and E-selectin-positive cells, also
increasing ICAM-1 expression evident by the shift in
ICAM-1 geo-mean value. HPAEC exposed to hASC-CM
did not show significant difference in the expression of
VCAM either in absence or presence of TNFα (data not
shown). Percentage of ICAM-positive cells detected in
the absence of TNFα was significantly suppressed by
hASC-CM treatment; however, this effect was not
detected in the presence of TNFα. On the contrary, E-
selectin expression (evident by geo-mean) was signifi-
cantly suppressed in the presence of TNFα.
hASC-CM effect on the activation of pro-apoptotic
pathways in endothelium
To elucidate whether anti-inflammatory effects of hASC-
CM are mediated by the suppression of pro-apoptotic
changes in endothelium, we assessed the level of caspase-3
cleavage in response to TNFα (Figure 11). TNFα induced
cleavage and activation of caspase-3 evident at 4 h. HPAEC
pretreated with hASC-CM showed a marked reduction of
cleaved caspase-3 level in response to TNFα. As caspases
activation is known to be regulated by pro-apoptotic and
anti-apoptotic members of Bcl2 family [31], we next investi-
gated whether levels of these proteins are affected by hASC
secreted factors. Levels of anti-apoptotic protein Bcl2 and
pro-apoptotic protein Bad did not change in HPAEC pre-
conditioned with hASC-CM. We did not observe consist-
ent increase in Bad phosphorylation (evident of Bad
deactivation) in response to hASC-CM pretreatment. How-
ever, exposure to hASC-secreted factors markedly reduced
the level of pro-apoptotic protein Bim.NHDF CM ASC CM
15minH2O2
. Preincubation of endothelial monolayers with hASC-CM suppressed















































































Figure 10 ASC-CM suppresses ICAM-1 and E-selectin expression by HPAEC. HPAEC were treated with vehicle control (NoPr, black bars),
NHDF-CM (DF-CM, grey bars), and hASC-CM (ASC-CM, white bars), and then stimulated with vehicle or 1 ng/ml TNFα (4 h). Harvested cells were
analyzed for the surface expression of ICAM-1 and E-selectin. Experiments with independent treatment/stimulation were repeated in triplicate.
T-test was used to assess the differences between analyzed groups. Exposure to hASC-CM lowers the percentage of ICAM-1-expressing quiescent
HPAEC and reduces the level of E-selectin expression in TNFα-stimulated HPAEC.
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Here, we demonstrate for the first time that administra-
tion of ASC-CM reduces indices of lung injury in the
LPS-induced ARDS model. Although autologous ASC can
be easily isolated from liposuction material within hours
of the patient admission to ICU [16], the ability to avoid
this procedure and use an “off-the-shelf” therapeutic prod-
uct could be a significant advantage for the treatment of
critically ill patient. Another potential advantage of the use
of conditioned medium is the absence of concerns associ-
ated with the possibility of cells homing toward pre-
existing tumors [32] or causing thromboemboli [33].
Previously, we have demonstrated that ASC-CM admin-
istration is able to prevent and reverse brain hypoxic-
ischemic injury [34]. Here, we assessed whether ASC-CM
would exhibit an ability to prevent development of LPS-
induced lung injury. Our study showed that a singleadministration of ASC-CM limited lung inflammatory
histological changes, protein extravasation to airspaces,
accumulation of inflammatory mediators TNFα and IL6 in
BALF, and the ability of BALF WBC to generate ROS. One
limitation of this study was that ARDS indices were ana-
lyzed via procedures requiring animal termination, which
limits the assessment of precise kinetics of the response.
We observed that ASC-CM-mediated suppression of LPS-
induced neutrophil infiltration showed a trend parallel to
ASC, yet did not reach significance at 48 h post-injection.
We also did not detect the suppression of LPS-induced
vascular leakage at this time point. We can only speculate
whether the suppression of LPS-induced neutrophil infiltra-
tion and vascular leakage by ASC-CM is significant at the
earlier time points in our model; however, it is to be ex-
pected that sustained retention of cells in the inflamed lung
would elicit more profound effects than the bolus injection
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Figure 11 ASC-CM suppresses activation of pro-apoptotic pathways in HPAEC. HPAEC were treated with vehicle control, NHDF-CM, and
hASC-CM, and then stimulated with indicated concentration of TNFα (4 h). Cell lysates were analyzed with antibodies to cleaved caspase 3, Bad,
phospho-Bad, Bim, and Bcl2. β-actin staining was used as loading control.
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suggest that the ability of neutrophils to cause damage to
the parenchyma and epithelium via oxidative burst is
attenuated in the mice receiving ASC-CM. Moreover, our
in vitro data show that the abilities of endothelium to resist
H2O2-induced barrier dysfunction and TNF-induced pro-
inflammatory and pro-apoptotic changes are enhanced by
ASC secreted factors. We show here that the exposure of
endothelium to ASC-CM lowers the level of pro-apoptotic
protein Bim. All three Bim isoforms are known to induce
apoptosis [35]. Bim plays an important role in Bax/Bak-
mediated cytochrome C release and activation of caspase
cascade [36]. We believe that down-regulation of pro-
apoptotic proteins by ASC-secreted factors is a novel mech-
anism, contributing to alleviation of endothelial pathology
and pulmonary vascular dysfunction. Whether down-
regulation of pro-apoptotic proteins is observed in ARDS
lungs in response to ASC or ASC-CM therapy, is a subject
for future research.
In our in vivo model utilizing a single delivery of ASC-
CM, secreted factors showed somewhat inferior potencycompared to ASC, except for protein extravasation into
BALF. Increased protein extravasation results from a
leaky epithelial barrier, which is likely to be counteracted
by ASC-secreted factors, similar to the effect shown on
endothelium. Surprisingly, we did not detect a beneficial
effect of ASC on LPS-induced protein extravasation. We
assume that the host response to ASC engrafted into
inflamed lung is likely to be different from the host
response to a single delivery of ASC-secreted factors.
Specifically, our results show that ASC-CM treatment
causes marked reduction of LPS-induced VEGF level in
BALF, whereas ASC treatment had little effect on this
endpoint. VEGF secreted to airspace may facilitate long-
term tissue repair, but also temporarily contribute to the
compromise of barrier function. Therefore, the effect of
ASC on ARDS may involve an interplay between the
resident lung tissue responses and the infused ASC, with
the need to analyze temporal factors for the optimization
of therapy.
Recently, concentrated microvesicular fraction of the
conditioned media from bone marrow-derived MSC was
Lu et al. Journal of Translational Medicine  (2015) 13:67 Page 14 of 15shown to alleviate LPS-induced lung injury [37]. How-
ever, to achieve an effect comparable to the effect of cell
therapy, the vesicular fraction was concentrated from
the media conditioned with approximately 4 times the
amount of MSC used for injection. On the contrary, in
our experiments the media was concentrated from only
half the amount of ASC used for injection. These data
suggests that either the microvesicle preparation process
led to a partial loss of activity, or that bone marrow-
derived MSC therapy relies to a larger extent on cell-to-
cell transfer of bioactive material than on bioactive
material secretion.
The effects of ASC therapy on lung pathology may
include both cellular (e.g., mitochondrial transfer), as have
been proposed [26] as well as paracellular (secreted fac-
tors) mechanisms. This study indicates that a single dose
of factors secreted by ASC-CM is sufficient to limit several
indices of ARDS. Future studies should investigate if
continuous delivery of ASC-CM has increased efficacy in
this and other models of ARDS.
Conclusions
Systemic administration of ASC conditioned media dimin-
ishes LPS-induced lung injury by inhibiting protein ex-
travasation into BALF, neutrophil inflammatory response,
secretion of pro-inflammatory cytokines TNFα and IL6,
and histopathological changes of the lungs. Exposure of
endothelium to factors secreted by ASC attenuates endo-
thelial barrier dysfunction and pro-inflammatory and pro-
apoptotic changes. Suppression of pro-apoptotic pathways
is likely to be mediated by the down-regulation of certain
pro-apoptotic proteins in endothelium. Our findings pro-
vide novel insights into the paracrine mechanisms of
ASC’s beneficial effects in ARDS.
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